Article Text

Download PDFPDF
Clonidine was effective for reducing tamoxifen associated hot flashes in postmenopausal women with breast cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: In postmenopausal women receiving tamoxifen for breast cancer, does clonidine reduce hot flashes?


Randomised {allocation concealed*}, blinded {clinicians, patients, and outcome assessors},* placebo controlled trial with 12 weeks follow up.


University of Rochester Cancer Center Community Clinical Oncology Program, New York, United States.


198 postmenopausal women who had received adjuvant tamoxifen treatment for breast cancer for ≥1 month and who reported ≥1 hot flash per day. Exclusion criteria were concurrent chemotherapy or other endocrine treatment for breast cancer; use of antihypertensive drugs, monoamine oxidase inhibitors, L-dopa, piribedil, tricyclic antidepressants, or sedatives; coronary insufficiency; myocardial infarction in the previous 3 months; symptomatic cardiac disease; peripheral or cerebrovascular disease; syncope; symptomatic hypertension; inability to tolerate clonidine; or abnormal renal or hepatic function. 194 women provided baseline data (mean age 54 y). Follow up was 91% at week 4, …

View Full Text


  • Source of funding: National Cancer Institute.

  • For correspondence: Dr K J Pandya, University of Rochester Cancer Center, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA. Fax +1 716 2731051.

  • * See glossary.

  • †: Information provided by author.